NEWS

MD Anderson Cancer Center & Dana–Farber Cancer Institute

Researchers from Tempus partnered with MD Anderson Cancer Center and the Dana-Farber Cancer Institute to study the value of germline testing in patients with advanced cancer.  Recent studies have found that 12-17% of cancer patients carry pathogenic germline variants (genetic alterations) that translate to cancer predisposition. Despite this, many cancer patients do not meet guidelines for testing and these germline pathogenic variants go undetect...